<DOC>
	<DOCNO>NCT00103753</DOCNO>
	<brief_summary>Thalassemia major genetic disorder affect hemoglobin synthesis , render individual dependent upon lifelong blood transfusion . Consequently , iron overload occur patient shortened life expectancy common cause death heart failure . This trial test whether combination traditional therapy ( deferoxamine ) new drug ( deferiprone ) prove effective removing cardiac iron deferoxamine alone .</brief_summary>
	<brief_title>Combined Chelation Treatment With Deferiprone Deferoxamine Thalassemia Major</brief_title>
	<detailed_description>Thalassemia Major ( TM ) hereditary anemia result single gene defect result abnormal red cell production . The survival affect individual dependent upon lifelong blood transfusion . Unfortunately , cause total body iron overload , 50 % patient UK dead age 35 . Approximately 70 % death result heart failure result consequence cardiac iron toxicity . A Cardiovascular Magnetic Resonance ( CMR ) technique ( exploits fact T2* signal decay relate tissue iron ) develop Royal Brompton Hospital provide non-invasive reproducible assessment cardiac iron . CMR therefore provide useful method ass response new treatment condition . Using cardiac T2* primary endpoint , investigate whether oral chelator , deferiprone combination traditional treatment ( deferoxamine ) , superior remove cardiac iron compare deferoxamine alone . This trial provide first randomize control , double-blinded , evidence efficacy combination treatment TM .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Beta thalassemia major Maintaining pretransfusion hemoglobin 9 g/dL Myocardial T2* 8 20 m Ability give inform consent Male female Age &gt; 18 year Any ejection fraction Confirmation effective contraception throughout trial ( men woman ) Implant incompatible MR ( magnetic resonance ) , pacemaker , claustrophobia , condition make CMR impossible inadvisable Neutropenia within 12 month ( ANC &lt; 1.5 x10^9/L ) , unless normal screen Thrombocytopenia within 12 month ( &lt; 50 x10^9/L ) , unless normal screen Liver enzymes &gt; 3 time upper limit normal Patients previously receive deferiprone total 6 month last 5 year . Patients previous reaction deferiprone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>Deferoxamine</keyword>
	<keyword>Iron chelation</keyword>
	<keyword>Beta Thalassemia Major</keyword>
</DOC>